Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

BACKGROUND: This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. METHODS: A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, B Douglas, Beach, Charles L, Mahmoud, Dalia, Weber, Laura, Henk, Henry J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994315/
https://www.ncbi.nlm.nih.gov/pubmed/24666795
http://dx.doi.org/10.1186/2162-3619-3-10
Descripción
Sumario:BACKGROUND: This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. METHODS: A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012. RESULTS: Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007) and a lower risk of hospitalization (HR 0.787, p = 0.02) compared to treatment with decitabine. CONCLUSIONS: This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests that azacitidine may result in clinically superior outcomes than decitabine.

Ejemplares similares